DUBLIN--(
BUSINESS WIRE
)--The
"Australia Non-Invasive Prenatal Testing (NIPT) Market: Focus on Technology, Method, Application, and End User - Forecast, 2024-2033"
report has been added to
ResearchAndMarkets.com's
offering.
The Australia non-invasive prenatal testing (NIPT) market, initially valued at $40.0 million in 2023, is set for substantial growth, projected to surge to $110.7 million by 2033, marking a remarkable compound annual growth rate (CAGR) of 10.71% over the period from 2024 to 2033.
The base year considered for the calculation of the market size is 2023. A historical year analysis has been done for the period FY2019-FY2022. The market size has been estimated for FY2023 and projected for the period FY2024-FY2033.
The Australia non-invasive prenatal testing (NIPT) market shows promising growth, driven by increasing awareness, rising maternal age, and advanced diagnostic technologies. Expanding healthcare access and a preference for non-invasive methods contribute to demand, with potential growth through innovation and competitive pricing strategies.
Industrial Impacts
The Australia non-invasive prenatal testing (NIPT) market is set for steady growth, driven by broader advancements in diagnostic testing and healthcare services. As healthcare systems evolve, there is a growing emphasis on non-invasive, cost-effective diagnostic solutions, particularly in prenatal care. Technological advancements and the increasing focus on precision medicine are enhancing the accuracy and accessibility of genetic screenings. The expansion of diagnostic capabilities and a rising demand for safer, more reliable testing methods are likely to propel the adoption of non-invasive prenatal testing (NIPT).
Increasing maternal age and growing awareness of genetic conditions further contribute to the demand for non-invasive prenatal testing (NIPT). The Australia healthcare system's ongoing improvements, including funding for advanced medical technologies, provide a conducive environment for market growth. Moreover, policy reforms and healthcare initiatives aimed at expanding access to genetic testing in both urban and rural settings are expected to boost market penetration.
NGS Technology Segment to Dominate the Australia Non-Invasive Prenatal Testing (NIPT) Market (by Technology)
Based on technology, the Australia non-invasive prenatal testing (NIPT) market was led by the NGS technology segment, which held a 54.75% share in 2023. next-generation sequencing (NGS) offers highly accurate, non-invasive genetic screening using a simple maternal blood sample. This technology enables the detection of chromosomal abnormalities, such as trisomies 13, 18, and 21, by analyzing cell-free DNA (cfDNA) fragments from the mother's blood. Non-invasive prenatal testing (NIPT) using NGS works by identifying specific genetic markers within the cfDNA to assess the risk of chromosomal abnormalities in the fetus. The test provides early results, typically within 5-7 days, allowing parents to make informed decisions early in their pregnancy.
For instance, Illumina, Inc.'s VeriSeq NIPT Solution v2 is a next-generation sequencing-based non-invasive prenatal testing (NIPT) with approximately 99.9% sensitivity. It is a streamlined, accessible solution that offers clinicians reliable results and enables sample reporting in about 26 hours.
cfDNA Segment to Dominate the Australia Non-Invasive Prenatal Testing (NIPT) Market (by Method)
Based on the method, the Australia non-invasive prenatal testing (NIPT) testing market was led by the cfDNA method segment, which held an 87.25% share in 2023. Cell-free DNA (cfDNA) testing is a widely used method in Australia's non-invasive prenatal testing (NIPT) market, allowing for the detection of fetal chromosomal abnormalities by analyzing small fragments of fetal DNA in maternal blood. This method offers high accuracy and minimal risk compared to invasive techniques such as amniocentesis.
For instance, F. Hoffmann-La Roche Ltd. offers Harmony Test, a prominent offering that utilizes cfDNA technology to screen trisomies 13, 18, and 21 with proven clinical precision. Similarly, Victorian Clinical Genetics Services Limited provides the percept NIPT, leveraging cfDNA to ensure effective early detection of chromosomal anomalies. Healius Limited (Genetic Diagnostics) expands the cfDNA-based offerings with its Generation NIPT, Generation 46, and Generation Plus, which cater to diverse testing needs, including comprehensive assessments for microdeletions and rare genetic conditions. These examples highlight the integral role of cfDNA methods in Australia's non-invasive prenatal testing (NIPT) advancements.
Trisomy Detection Segment to Dominate the Australia Non-Invasive Prenatal Testing (NIPT) Market (by Application)
Based on application, the Australia non-invasive prenatal testing (NIPT) testing market was led by the trisomy detection application segment, which held a 56.50% share in 2023. Trisomy detection is one of the primary applications of non-invasive prenatal testing (NIPT), focusing on identifying chromosomal abnormalities such as Trisomy 21 (Down Syndrome), Trisomy 18 (Edwards Syndrome), and Trisomy 13 (Patau Syndrome).
These conditions occur when there are three copies of a chromosome instead of the normal two, leading to fetal developmental and health complications. For instance, tests offered by Sonic Healthcare, F. Hoffmann-La Roche Ltd., and Healius Limited, among others, namely, percept NIPT, Harmony, and Generation NIPT, offer a highly accurate and reliable method for detecting these trisomies by analyzing cell-free fetal DNA (cffDNA) present in maternal blood.
Australia non-invasive prenatal testing (NIPT) market was led by the hospital and clinics segment, which held a 72.25% share in 2023.
The dominance of hospitals in the Australia non-invasive prenatal testing (NIPT) market is underscored by their pivotal role in providing comprehensive healthcare services and incorporating non-invasive prenatal testing (NIPT) into their services to enhance the range of prenatal diagnostics offered to expectant parents.
This segment involves the utilization of non-invasive prenatal testing (NIPT) technologies within hospital facilities, allowing for efficient and accurate screening of genetic abnormalities in the fetus. Hospitals may also exist in the private sector, owned by for-profit or nonprofit organizations. In the case of private hospitals, funding is sourced from patients' direct payments for medical services, insurance coverage, government support through national health insurance initiatives, or financial assistance from foreign embassies.
How can this report add value to an organization?
Product/Innovation Strategy: The Australia non-invasive prenatal testing (NIPT) market has been extensively segmented based on various categories, such as technology, method, application, and end user. This can help readers understand which segments account for the largest share and which are well-positioned to grow in the coming years.
Growth/Marketing Strategy: Mergers, acquisitions, and product launches accounted for the minimal number of key developments, i.e., nearly 30.61% of the total developments in the Australia non-invasive prenatal testing (NIPT) market were between January 2019 and September 2024.
Competitive Strategy: The Australia non-invasive prenatal testing (NIPT) market has numerous established players with product portfolios. Key players in the Australia non-invasive prenatal testing (NIPT) market analyzed and profiled in the study involve established players offering products for Australia non-invasive prenatal testing (NIPT).
Key Market Players and Competition Synopsis
Victorian Clinical Genetics Services Limited
Healius Limited
F. Hoffmann-La Roche Ltd
Illumina, Inc.
Novacyt
BGI Genomics
Natera, Inc.
Monash IVF Group
Virtus Health
Sonic Healthcare Limited
PathWest Laboratory Medicine
Key Attributes:
Report Attribute
Details
No. of Pages
70
Forecast Period
2024 - 2033
Estimated Market Value (USD) in 2024
$44.3 Million
Forecasted Market Value (USD) by 2033
$110.7 Million
Compound Annual Growth Rate
10.7%
Regions Covered
Australia
Key Topics Covered:
Executive Summary
Scope and Definition
1 Markets
1.1 Market Outlook
1.2 Key Findings
1.3 Australia Market Scenario
1.3.1 Realistic Scenario
1.3.2 Optimistic Scenario
1.3.3 Pessimistic Scenario
1.4 Industry Outlook
1.4.1 Trends
1.4.1.1 Expanding Application of Non-Invasive Prenatal Testing (NIPT) Products
1.4.2 Regulatory Landscape
1.4.3 Product Benchmarking
1.5 Business Dynamics
1.5.1 Impact Analysis
1.5.2 Business Drivers
1.5.2.1 High Incidence of Genetic Disorders
1.5.2.2 Rising Maternal Age
1.5.2.3 Rising Adoption of Non-Invasive Prenatal Testing
1.5.3 Business Restraints
1.5.3.1 Lack of Awareness Regarding Non-Invasive Prenatal Testing (NIPT)
1.5.4 Business Opportunities
1.5.4.1 Expansion of NIPT Accessibility and Coverage
2 Australia Non-Invasive Prenatal Testing (NIPT) Market, Test Volume
2.1 Test Volume
3 Australia Non-Invasive Prenatal Testing (NIPT) Market, by Technology
3.1 Opportunity Assessment
3.2 Growth-Share Matrix
3.2.1 NGS
3.2.2 PCR
3.2.3 Others
4 Australia Non-Invasive Prenatal Testing (NIPT) Market, by Method
4.1 Opportunity Assessment
4.2 Growth-Share Matrix
4.2.1 cfDNA
4.2.2 FCMB
5 Australia Non-Invasive Prenatal Testing (NIPT) Market, by Application
5.1 Opportunity Assessment
5.2 Growth-Share Matrix
5.2.1 Trisomy Detection
5.2.2 Microdeletion Detection
5.2.3 Sex Chromosome Aneuploidy Detection
5.2.4 Others
6 Australia Non-Invasive Prenatal Testing (NIPT) Market, by End User
6.1 Opportunity Assessment
6.2 Growth-Share Matrix
6.2.1 Hospital and Clinics
6.2.2 Diagnostic Laboratories
6.2.3 Others
7 Company Profiles
7.1 Overview
7.2 Top Products/Service
7.3 Top Competitors
7.4 Key Personnel
7.5 Analyst View
8 Research Methodology
For more information about this report visit
https://www.researchandmarkets.com/r/tbu1p1
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
